Southey, M.C., Goldgar, D., Cox, A. orcid.org/0000-0002-5138-1099 et al. (1 more author) (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics. 103839. ISSN 0022-2593
Abstract
Background: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated with breast cancer risk as high as those associated with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare variants in PALB2, CHEK2 and ATM via a multi-centre case-control study. Methods: We genotyped ten rare mutations using the custom iCOGS array: PALB2 c.1592delT, c.2816T>G and c.3113G>A, CHEK2 c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, and c.1343T>G and ATM c.7271T>G. We assessed associations with breast cancer risk (42,671 cases and 42,164 controls), as well as prostate (22,301 cases and 22,320 controls) and ovarian cancer (14,542 cases and 23,491 controls) risk, for each variant. Results: For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39-8.52; p=7.1x10-5), PALB2 c.3113G>A OR 4.21 (95% CI 1.84-9.60; p=6.9x10-8) and ATM c.7271T>G OR 11.0 (95% CI 1.42-85.7; p=0.0012). We also found evidence of association with breast cancer risk for three variants in CHEK2, c.349A>G, c.1036C>T and c.538C>T (p ≤ 0.017). Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53-6.03; p=0.0006) for African men and CHEK2 c.1312G>T (OR 2.21 95% CI 1.06-4.63; p=0.030) for European men. No evidence of association with ovarian cancer was found for any of these variants. Conclusion: This report adds to accumulating evidence that at least some variants in these genes are associated with an increased risk of breast cancer that is clinically important.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) The University of Sheffield > Sheffield Teaching Hospitals |
Funding Information: | Funder Grant number YORKSHIRE CANCER RESEARCH S299 CANCER RESEARCH UK (CRUK) C5410/A7315. |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 28 Jun 2016 08:40 |
Last Modified: | 29 Sep 2016 14:03 |
Published Version: | https://dx.doi.org/10.1136/jmedgenet-2016-103839 |
Status: | Published |
Publisher: | BMJ Publishing Group |
Refereed: | Yes |
Identification Number: | 10.1136/jmedgenet-2016-103839 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:101487 |
Download
Filename: J Med Genet-2016-Southey-jmedgenet-2016-103839.pdf
Licence: CC-BY 4.0